Neurocognitive Enhancement in Major Depressive Disorder (MDDNET)
This study has been completed.
Sponsor:
Queen's University
Information provided by (Responsible Party):
Christopher Bowie, Queen's University
ClinicalTrials.gov Identifier:
NCT00998569
First received: October 14, 2009
Last updated: March 20, 2012
Last verified: March 2012
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
The purpose of this study is to examine the effects of neurocognitive enhancement on cognitive abilities and related social and adaptive behaviours in individuals diagnosed with major depressive disorder. Subjects in this study will be randomized to receive Neurocognitive Enhancement Therapy (NET) or to a wait list and then NET . Secondary aims include examining whether the cognitive benefits are potentiated by repeated exposure during in-home practice with complementary exercises. Additionally, the investigators will examine the durability of the effects and their generalization to functional capacity and everyday functional performance after completion of the groups.
| Condition | Intervention |
|---|---|
|
Major Depressive Disorder |
Behavioral: Neurocognitive Enhancement Behavioral: Wait List Control |
| Study Type: | Interventional |
| Study Design: | Allocation: Randomized Endpoint Classification: Efficacy Study Intervention Model: Crossover Assignment Masking: Double Blind (Subject, Outcomes Assessor) Primary Purpose: Treatment |
| Official Title: | Neurocognitive Enhancement in Major Depressive Disorder |
Resource links provided by NLM:
Further study details as provided by Queen's University:
Primary Outcome Measures:
- Performance on paper and pencil assessments of neurocognition after treatment, compared to baseline assessment performance [ Time Frame: 20 weeks ] [ Designated as safety issue: No ]
| Enrollment: | 33 |
| Study Start Date: | October 2009 |
| Study Completion Date: | March 2012 |
| Primary Completion Date: | March 2012 (Final data collection date for primary outcome measure) |
| Arms | Assigned Interventions |
|---|---|
| Experimental: Neurocognitive Enhancement |
Behavioral: Neurocognitive Enhancement
Neurocognitive Enhancement Therapy (NET) uses behavioural treatment strategies that are designed to improve a range of cognitive skills. NET uses strategies such as coaching, repetition, practice, teaching, group discussion, and compensation for deficits by using cognitive strengths.
|
| No Intervention: Wait List |
Behavioral: Wait List Control
Participants will be wait listed for 10 weeks, following which time they will receive the intervention previously described.
|
Eligibility| Ages Eligible for Study: | 18 Years to 65 Years |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Criteria
Inclusion Criteria:
- Male or Female.
- Subjects will be between the ages of 18 and 65, which is the age range with available normative comparison data.
Exclusion Criteria:
- Presence of a medical diagnosis that is associated with known cognitive impairments, such as multiple sclerosis, cerebrovascular accident, dementia, or history of traumatic brain injury.
- Subjects with a reading level below grade 6, as assessed with the Wide Range Achievement Test - Reading Recognition Subtest, will be excluded because of the likelihood of not understanding task instructions.
- Subjects with uncorrectable vision or hearing impairment that would preclude valid assessments or intervention procedures.
Contacts and Locations More Information
No publications provided
| Responsible Party: | Christopher Bowie, Ph.D., Queen's University |
| ClinicalTrials.gov Identifier: | NCT00998569 History of Changes |
| Other Study ID Numbers: | PSYC-092-09 |
| Study First Received: | October 14, 2009 |
| Last Updated: | March 20, 2012 |
| Health Authority: | Canada: Health Canada |
Additional relevant MeSH terms:
|
Depressive Disorder Depression Depressive Disorder, Major |
Mood Disorders Mental Disorders Behavioral Symptoms |
ClinicalTrials.gov processed this record on June 17, 2013